Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has opened its first Phase II trial for PEG-SN38 (EZN-2208), its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE